Dietary Supplement Climea Forte 30tabs.

Product Information

Table 1: Treatment-Emergent Adverse Reactions Reported at a Frequency of ≥ 5 Percent and More Frequent in Women Receiving Climara Forte Moderate] Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used. Preparat zawiera wyciągi roślinne iwitaminy. 1tabletka zawiera: 50 mg izoflawonów znasion soi, 30 mg wyciągu zszyszek chmielu, 10 mg wyciągu znasion lnu, 400 mg wapnia, 5µg witaminy D3, 1,4 mg witaminy B6, 12 mg witaminy E, 0,2 mg kwasu foliowego. Climea Forte, a special supplement that affects the well-being and alleviate the discomfort of women, associated with menopause. The composition of the preparation is a double dose of soy isoflavones, which are classified as phytoestrogens - or plant counterparts of female hormones. Soy isoflavones are safe and have a mild effect on the endocrine women - without causing side effects. Due to the increased content of calcium and vitamin D3 Climea forte, also it allows you to maintain the proper structure and bone density. Enriched with the preparation that improves the appearance of the skin, and also relieves symptoms of fatigue and irritability associated with the menopause. In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) was reported in women receiving estrogen-alone compared to placebo 2.

Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.Climea Forte helps in relieving the symptoms of menopause, including hot flushes, sweating, anxiety, irritability (hops extract). Supports weight control and helps maintain digestive comfort (flax). Supports the maintenance of healthy bones (calcium and vitamin D), contributes to the reduction of tiredness and fatigue (vitamin B6, folates). Also helps to protect cells against oxidative stress (vitamin E) and supports the proper functioning of the nervous system (vitamin B6). In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted. Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately.

Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, and increased triglyceride levels. Retinal vascular thrombosis has been reported in women receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, estrogens should be permanently discontinued. Addition Of A Progestin When A Woman Has Not Had A Hysterectomy chinolinowa oraz żółcień pomarańczowa mogą mieć szkodliwy wpływ na aktywność i skupienie uwagi u dzieci.

Food Interaction

Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA. 2007;297:1465-1477.

Swimming, bathing, or using a sauna while using Climara Forte has not been studied, and these activities may decrease the adhesion of the system and the delivery of estradiol. Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-l-antitrypsin, ceruloplasmin). The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the WHI substudy of daily CE (0.625 mg)-alone. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer [relative risk (RR) 0.80] 5.Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med. 2006;166:357-365. https://www.termedia.pl/Wplyw-zmian-hormonalnych-zachodzacych-w-organizmie-kobiety-na-stan-skory,56,12608,0,0.html Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen. Climara Forte Hypertension interaction An increased risk of stroke and DVT has been reported with estrogen-alone therapy. An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately. Climea forte содржи изофлавони од соја збогатени со лен, кој помага за контрола на телесната тежина и екстракт од хмељ, благодарение на кој ги ублажува симптомите на менопауза. Дополнително, додатокот во исхраната Climea forte содржи калциум и витамин Д3, кои помагаат за одржување на здрави коски и витамин Б6, придонесувајќи за намалување на замор и замор во менопаузата. Индикации

https://www.poradnikzdrowie.pl/uroda/kosmetyki/kolagen-wlasciwosci-dlaczego-jest-potrzebny-aa-CPEN-tGPd-KgaG.html CLIMEA Forte PLUS to preparat którego zadaniem jest złagodzenie objawów menopauzy oraz profilaktycznie w osteoporozie. Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary. Treatment Of Moderate To Severe Vasomotor Symptoms Due To MenopauseThe data described below reflect pooled data from 5 clinical trials of Climara Forte. A total of 614 women were exposed to Climara Forte for 3 months (193 women at 0.025 mg per day, 201 women at 0.05 mg per day, 194 women at 0.1 mg per day) in randomized, double-blind trials of clinical efficacy versus placebo and versus active comparator. All women were postmenopausal, had a serum estradiol level of less than 20 pg/mL, and a minimum of five moderate to severe hot flushes per week or a minimum of 15 hot flushes per week of any severity at baseline. Included in this table are an additional 25 postmenopausal hysterectomized women exposed to Climara Forte 0.025 mg per day for 6 to 24 months (N=16 at 24 months) in a randomized, double-blind, placebo-controlled study of Climara Forte for the prevention of osteoporosis. If your personal data are processed based on your consent, you may withdraw your consent to personal data processing at any time, whereas this will not affect lawfulness of prior processing. The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. Climara Forte should be applied immediately after opening the pouch and removing the protective liner. In the WHIMS estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years 8.